ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

26 Aug 2025 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

12 Aug 2025 04:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

05 Aug 2025 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

28 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

15 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

10 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

13 May 2025 04:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

07 May 2025 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

06 May 2025 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

02 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

27 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

26 Mar 2025 05:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

20 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

19 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

12 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

10 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

09 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 Nov 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

12 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

11 Nov 2024 13:00:00 By Nasdaq GlobeNewswire